J&J touts suc­cess of Vyv­gart com­peti­tor in two au­toim­mune dis­ease tri­als, in­clud­ing key myas­the­nia gravis study

John­son & John­son’s ex­per­i­men­tal an­ti­body nipocal­imab re­duced the sever­i­ty of symp­toms re­lat­ed to two au­toim­mune con­di­tions — first in a piv­otal study for gen­er­al­ized myas­the­nia gravis, and al­so in a mid-stage tri­al in Sjö­gren’s dis­ease.

In the Phase III study for gen­er­al­ized myas­the­nia gravis, a dis­ease which caus­es mus­cle weak­ness, nipocal­imab sig­nif­i­cant­ly re­duced symp­tom scores from base­line mea­sured over weeks 22 to 24 com­pared with place­bo, the Big Phar­ma an­nounced Mon­day. Myas­the­nia gravis pri­mar­i­ly im­pacts mus­cles of the eye and oth­er parts of the face, as well as in the limbs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER